We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Breast Cancer Cells Characterized by Microspectroscopy

By LabMedica International staff writers
Posted on 05 Nov 2012
A diagnostic tool has been developed that identifies the metastatic ability of breast cancer cells based on the characterization of the lipid component of the cells. More...


The characterization of the lipids associated with malignancy has been possible due to technological development of a spectroscopic device named Raman (RS) and forms the basis for introducing this technique in routine cytological diagnosis.

Scientists at the Bellvitge Biomedical Research Institute (IDIBELL; Barcelona, Spain) assessed the different profiling of the lipid composition of breast cancer cells, which permitted differentiation of the lipogenic phenotype according to the proportion of unsaturated fatty acids. The investigators cultured breast cancer cells and applied immunochemistry, before submitting the samples to Raman microspectroscopy

The Renishaw Raman system (Apply Innovation; Wotton-under-Edge, UK) comprises of a 514 nm laser that supplies an excitation beam of about 10 mW power, which is focused onto the sample via a microscope. The cytoplasm lipids were measured by RS in a position near the nucleus and outside the endoplasmic reticulum area, where the Nile red staining showed major lipid concentration. The lipid phenotype associated to breast cancer malignancy belongs to Raman spectra acquired in the range of 2,820-3,030 cm−1.

The authors concluded that Raman spectroscopy is a promising technique in biomedical studies due to its noninvasive character and high specificity. The cytology techniques used have found a correlation between the activation of lipogenesis, the chemical reaction leading to fatty acids in an organism, and the amount of saturated fats in metastatic cells indicating a worse prognosis and a decreased survival. The lipid content of the breast cancer cells might be a useful measure to determine various functions coupled to the progression of breast cancer. Àngels Sierra, PhD, the senior author, said, “The algorithm for the discrimination of the metastatic ability is a first step towards the stratification of breast cancer cells using this quick and reactive tool." The study was published on October 17, 2012, in the journal Public Library of Science ONE.

Related Links:

Bellvitge Biomedical Research Institute
Apply Innovation



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.